KPTI8:59 AMKaryopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical OncologyTrial Results • Phase 3ASCO oral presentation Tue, Jun 2, 2026, 9:45 AM CTGkaryopharm.com
KPTI7:00 AMKaryopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume ReductionTrial Results • Phase 3karyopharm.com